Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology

被引：22

作者：

Naito, Yoichi ^{[1
,18
]}

Mishima, Saori ^{[1
,17
]}

Akagi, Kiwamu ^{[2
,18
]}

Igarashi, Ataru ^{[3
,17
]}

Ikeda, Masafumi ^{[1
,17
]}

Okano, Susumu ^{[1
,17
]}

Kato, Shunsuke ^{[4
,18
]}

Takano, Tadao ^{[5
,17
]}

Tsuchihara, Katsuya ^{[1
,17
]}

Terashima, Keita ^{[6
,17
]}

Nishihara, Hiroshi ^{[7
,18
]}

Nishiyama, Hiroyki ^{[8
,17
]}

Hiyama, Eiso ^{[9
,17
]}

Hirasawa, Akira ^{[10
,17
]}

Hosoi, Hajime ^{[11
,16
,17
]}

Maeda, Osamu ^{[12
,18
]}

Yatabe, Yasushi ^{[13
,17
]}

Okamoto, Wataru ^{[9
,18
]}

Ono, Shigeru ^{[14
,19
]}

Kajiyama, Hiroaki ^{[12
,17
]}

Nagashima, Fumio ^{[15
,17
]}

Hatanaka, Yutaka ^{[16
,18
]}

Miyachi, Mitsuru ^{[11
,16
]}

Kodera, Yasuhiro ^{[12
,17
]}

Yoshino, Takayuki ^{[1
,18
]}

Taniguchi, Hiroya ^{[1
,17
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[2] Saitama Canc Ctr, Saitama, Japan

[3] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan

[4] Juntendo Univ, Tokyo, Japan

[5] Tohoku Univ, Sendai, Miyagi, Japan

[6] Natl Ctr Child Hlth & Dev, Tokyo, Japan

[7] Keio Univ, Tokyo, Japan

[8] Tsukuba Univ, Ibaraki, Japan

[9] Hiroshima Univ Hosp, Hiroshima, Japan

[10] Okayama Univ, Okayama, Japan

[11] Kyoto Prefectural Univ Med, Kyoto, Japan

[12] Nagoya Univ Hosp, Nagoy, Japan

[13] Natl Canc Ctr, Tokyo, Japan

[14] Jichi Med Univ, Shimotsuke, Tochigi, Japan

[15] Kyorin Univ, Fac Med, Tokyo, Japan

[16] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan

[17] Japan Soc Clin Oncol, Tokyo, Japan

[18] Japanese Soc Med Oncol, Tokyo, Japan

[19] Japanese Soc Pediat Hematol Oncol, Tokyo, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 25卷 / 03期

关键词：

Neurotrophic receptor tyrosine kinase (NTRK) fusion; Tropomyosin receptor kinase (TRK) inhibitor; Advanced solid tumor; Tumor-agnostic treatment; Clinical practice guideline; ETV6-NTRK3 GENE FUSION; ANALOG SECRETORY CARCINOMA; IMMUNOHISTOCHEMISTRY; EXPRESSION; LANDSCAPE;

D O I：

10.1007/s10147-019-01610-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy of tropomyosin receptor kinase inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors have been established as the second tumor-agnostic treatment, making it necessary to develop the guideline prioritized for these patients. Methods Clinical questions regarding medical care were formulated for patients with NTRK-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and Japanese Society of Pediatric Hematology/Oncology, and the public comments among all Societies' members was done. Results The current guideline describes 3 clinical questions and 15 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors. Conclusion In the NTRK guideline, the committee proposed 15 recommendations for performing NTRK testing properly to select patients who are likely to benefit from tropomyosin receptor kinase inhibitors.

引用

页码：403 / 417

页数：15

共 45 条

[1]

Abel H., 2015, CLIN GENOMICS, P151

[2] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types [J].

Amatu, Alessio ;

Sartore-Bianchi, Andrea ;

Siena, Salvatore .

ESMO OPEN, 2016, 1 (02)

[3]

[Anonymous], NICEGIDTA10229

[4]

[Anonymous], CADTHPCODR10159

[5]

[Anonymous], NICEGIDTA10414

[6]

[Anonymous], CADTHPCODR10157

[7] Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma [J].

Bishop, Justin A. ;

Yonescu, Raluca ;

Batista, Denise ;

Begum, Shahnaz ;

Eisele, David W. ;

Westra, William H. .

HUMAN PATHOLOGY, 2013, 44 (10) :1982-1988

[8] Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors [J].

Bourgeois, JM ;

Knezevich, SR ;

Mathers, JA ;

Sorensen, PHB .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (07) :937-946

[9] Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST [J].

Brenca, Monica ;

Rossi, Sabrina ;

Polano, Maurizio ;

Gasparotto, Daniela ;

Zanatta, Lucia ;

Racanelli, Dominga ;

Valori, Laura ;

Lamon, Stefano ;

Dei Tos, Angelo Paolo ;

Maestro, Roberta .

JOURNAL OF PATHOLOGY, 2016, 238 (04) :543-549

[10] NTRK fusion-positive cancers and TRK inhibitor therapy [J].

Cocco, Emiliano ;

Scaltriti, Maurizio ;

Drilon, Alexander .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :731-747

← 1 2 3 4 5 →